GET DAILY SIGNALSIndivior (INDV) Delivers Record Q3 Results Powered by SUBLOCADE Growth
Key Takeaways
- Indivior Pharmaceuticals reported Q3 2026 total net revenue of $356 million, up 13% year over year and above the roughly $329 million consensus estimate.
- Diluted earnings per share (EPS) came in at $1.12 on a GAAP basis, while non-GAAP EPS of $1.32 beat analyst expectations by about $0.19.
- Record quarterly SUBLOCADE net revenue of $267 million, up 22% year over year, drove the top-line acceleration.
- Net income climbed to $137 million from $42 million in the prior-year period, marking a record quarter.
- Full-year 2026 guidance was reaffirmed as adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) margin expanded sharply.
- For more context on this ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore these dedicated pages.
- Discover automated strategies with Trending AI Robots to see how AI-driven trading models are navigating the current market.
Why This Quarter Stands Out
Indivior Pharmaceuticals is a specialty pharmaceutical company focused on treatments for opioid use disorder (OUD) and other substance-use conditions, led by its long-acting injectable therapy SUBLOCADE. This quarterly report matters because it shows whether the company can keep converting SUBLOCADE's growth into stronger profitability while managing legacy competition for its sublingual products. The results also arrive against the backdrop of a pending all-stock merger with Supernus Pharmaceuticals and a recently declared special cash dividend, making the earnings trajectory central to how investors assess the combined company's near-term value. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The Numbers Behind the Report
For the third quarter ended September 30, 2026, Indivior reported total net revenue of $356 million, a 13% increase from $314 million a year earlier and above the consensus estimate of approximately $329 million. Growth was led by SUBLOCADE, which generated record net revenue of $267 million, up 22% year over year.
GAAP (Generally Accepted Accounting Principles) net income reached a record $137 million, compared with $42 million in the prior-year quarter, producing diluted EPS of $1.12. Non-GAAP net income was a record $161 million, with non-GAAP diluted EPS of $1.32, beating estimates by roughly $0.19. The company highlighted an adjusted EBITDA margin of 59%, up 2,100 basis points year over year.
Management reaffirmed full-year 2026 guidance, including total net revenue of $1.3 billion to $1.37 billion and adjusted EBITDA of $700 million to $740 million, excluding the impact of the pending acquisition.
How the Market Is Responding
Investor sentiment around INDV has been shaped by both the company's accelerating financial performance and its pending all-stock merger with Supernus Pharmaceuticals. The top- and bottom-line beats, record SUBLOCADE revenue, and sharply higher adjusted EBITDA margin reinforce the view that the company's core growth engine remains strong. The previously declared special cash dividend of $8.13 per share and healthy cash generation, which brought cash and investments to $332 million at quarter end, have added to confidence heading into the merger. At the same time, some market participants remain focused on execution of the deal and on the durability of SUBLOCADE's double-digit growth trajectory.
What to Watch Going Forward
Looking ahead, investors should track whether SUBLOCADE can sustain its roughly 22% year-over-year growth, since the product is the primary driver of both revenue and margin expansion. Continued dispense unit growth and patient retention will be important signals of demand strength across the OUD treatment market.
The completion of the Supernus merger is another key catalyst. The transaction is expected to reshape the company's portfolio and cost structure, and management has noted that its reaffirmed 2026 guidance excludes the impact of the pending acquisition. Watch for updates on regulatory approvals, shareholder votes, and the expected closing timeline.
Finally, monitor cost and profitability trends, including adjusted EBITDA margin progression and operating expense discipline. Competitive dynamics in both the long-acting injectable and sublingual buprenorphine categories, along with any shifts in payer coverage or litigation developments, could also influence the company's ability to deliver on its full-year guidance.
Tools That Help Me Stay on Top of These Trends
One tool I’ve found helpful lately is Tickeron’s AI Screener. It lets me quickly filter stocks by technical patterns, fundamentals, and AI-driven signals so I can compare names like INDV against peers without spending hours on manual work. I’ve used it to spot similar growth stories in the sector and to build focused watchlists for earnings season.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
INDV's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for INDV turned positive on October 26, 2026. Looking at past instances where INDV's MACD turned positive, the stock continued to rise in 34 of 47 cases over the following month. The odds of a continued upward trend are 72%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where INDV's RSI Indicator exited the oversold zone, 22 of 32 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 69%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 43 of 62 cases where INDV's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 69%.
The Momentum Indicator moved above the 0 level on October 28, 2026. You may want to consider a long position or call options on INDV as a result. In 59 of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 65%.
Following a +0.61% 3-day Advance, the price is estimated to grow further. Considering data from situations where INDV advanced for three days, in 139 of 207 cases, the price rose further within the following month. The odds of a continued upward trend are 67%.
INDV may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The 50-day moving average for INDV moved below the 200-day moving average on October 22, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where INDV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 71%.
The Aroon Indicator for INDV entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 5 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-20.100) is normal, around the industry mean (8.801). P/E Ratio (12.240) is within average values for comparable stocks, (-2.500). Projected Growth (PEG Ratio) (0.060) is also within normal values, averaging (2.152). Dividend Yield (0.054) settles around the average of (0.044) among similar stocks. P/S Ratio (3.330) is also within normal values, averaging (178.797).
The Tickeron Profit vs. Risk Rating rating for this company is 42 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 55 (best 1 - 100 worst), indicating steady price growth. INDV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 64 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 93 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry PharmaceuticalsGeneric
Advertisement